Marshelle Smith Warren, MD, has been appointed chief medical officer of Dallas-based Secretome Therapeutics, a clinical-stage biotechnology company that is pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs).
The company said Warren is a highly experienced pharmaceutical executive with more than two decades of leadership in clinical development, translational medicine, and regulatory strategy across multiple therapeutic areas, including cell therapy, immunology, cardiovascular, and rare diseases.
Warren’s “world-class expertise in cell-based therapies and her history of leadership are invaluable as we execute ongoing clinical trials for STM-01, and as we design potentially pivotal studies in orphan forms of heart failure,” Secretome President and CEO Vinny Jindal said in a statement.
“Importantly, her depth of experience strengthens Secretome’s management team meaningfully as the company matures towards late-stage clinical studies and beyond,” Jindal added.
Most recently, Warren was chief medical officer at Massachusetts-based SQZ Biotechnologies, where she led the successful development of first-in-human cell therapy programs, culminating in its acquisition by STEMCELL Technologies in 2024.
Before that, she held senior clinical development roles at Atara Biotherapeutics, guiding strategy for allogeneic T-cell therapies, and at industry leaders Gilead Sciences and Amgen.
Warren has directly overseen the submission and execution of numerous Investigational New Drug applications, New Drug Applications, and Biologics License Applications, leading to multiple FDA and EMEA regulatory approvals with collective revenues exceeding $100 billion.
Throughout her career, Warren’s leadership has contributed to successful IPOs, corporate acquisitions, and strategic mergers, underscoring her expertise in navigating both clinical and corporate milestones in biotechnology, the company said.
“I’m excited to join the talented team at Secretome Therapeutics,” Warren said in a statement. “The company’s pioneering platform technology offers tremendous potential, and I look forward to leading our clinical development efforts and advancing groundbreaking therapies for patients facing serious health challenges.”
Don’t miss what’s next. Subscribe to Dallas Innovates.
Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.
R E A D N E X T
-
Baltimore-based Secretome has a presence at BioLabs at Pegasus Park in Dallas. The biotech company is at the forefront of developing "revolutionary solutions" aimed at harnessing the power of secretomes, naturally occurring molecules that promote healing and regeneration, HEST said.
-
Baltimore-based Secretome—which has a presence at BioLabs at Pegasus Park in Dallas and offices in Plano—said the financing will enable it to initiate clinical trials for its lead asset, STM-01, and further advance its drug development pipeline.
-
Renibus CEO Jeff Keyser will be acknowledged as the award recipient at the 10th Annual iC³ Life Science & Healthcare Innovation Summit on Thursday, the first day of the Oct. 3-4 summit at the Loews Arlington Hotel & Convention Center.
-
When AI rewrote the Barbie speech for nonprofits, it hit uncomfortably close to home from impossibly tight budgets to donor expectations. Social entrepreneur Suzanne Smith says it's time for leaders to dive in and try Gen AI for themselves.
-
Ray Kaczmarek—the former CEO of Genezen—is an expert in gene therapy manufacturing with decades of experience leading operations, technology, and commercial supply strategies at pharmaceutical and biotech companies, Nanoscope said.
